Deleted Tweets From Scott Gottlieb, R-D.C.

At #FDA, we’re working closely with @SecAzar on crafting policy to improve competition, access, and opportunity for patients to benefit from safe, effective, and lower cost biosimilar alternatives. https://t.co/VfyO1nOt1f

RT @SecAzar: Thank you @SGottliebFDA for showing me around @US_FDA yesterday. Keep up the great work! https://t.co/CvXKeucKwm

RT @annaedney: FDA Commissioner @SGottliebFDA goes after a “rigged payment scheme” between PBMs, insurers and pharma for keeping l… https://t.co/rsnW83K8rb

RT @Surgeon_General: This a.m. I was in TN learning about how Knox County formed a Naloxone Community Collaborative to inform citizens a… https://t.co/EPHu8Yfg1O

RT @SecAzar: The most powerful force in the #healthcare marketplace is a fully informed consumer. Greater transparency will help… https://t.co/2Uy3JF3KXN

RT @CDCDirector: More than 100 Americans die each day from #opioid overdoses – in every town across the nation. Here’s how we can re… https://t.co/xRHStw1Glh

RT @Reuters_Health: FDA head Gottlieb criticizes industry for 'Kabuki drug-pricing' https://t.co/jA4p6ewIwD

RT @CDCgov: Influenza activity has declined significantly, but will likely continue for several more weeks. Help stop the sprea… https://t.co/dsAEwjbd5W

RT @FDA_Track: Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA activities related to the ongoing post-market review o… https://t.co/sJXblrNjaA

My perspectives piece in @NEJM tonight with CBER Center Director Peter Marks on balanced innovation, access, and safety with cell-based regenerative medicine https://t.co/W6BBqSObRV

RT @HHSGov: Curious about #biosimilars? They are a safe and effective treatment options for patients. https://t.co/1DC8jak8hI… https://t.co/U2knIzNzSi

1/5 I want to provide brief update on shortage of IV saline products which was exacerbated by flu season, and impact of Hurricane Maria on medical product manufacturing sector in Puerto Rico.

RT @SecAzar: I spent some time at @US_FDA and @FDA_Drug_Info yesterday. I'm continually inspired by the great work being done by… https://t.co/qxbJ55TOiT

2/5 The products in shortage include large volume saline bags typically used to hydrate patients, such as those suffering from influenza, and small volume IV saline bags (generally in 50 and 100 ml sizes) that are often used to deliver other medicines.

New #FDA-authored special report in The New England Journal of Medicine says definitive studies regarding safety/efficacy of certain stem cell procedures are needed. Without studies, these therapies may be detrimental to patients, public health: https://t

Pleased to have co-authored a special report with @FDACBER Director Dr. Peter Marks made available today in The New England Journal of Medicine regarding the agency’s work balancing safety/innovation for cell-based regenerative medicine: https://t.co/9y0i

4/5 New manufacturers, Grifols and Fresenius Kabi, licensed last year, are now also online and producing saline products. Additionally, we’ve permitted imports of saline from 6 non-U.S. facilities and are encouraging them to get approval to help address t

3/5 We’ve actively work on improving large and small IV bag shortages for several months and continue to focus on this. In addition, existing manufacturers, most notably Baxter, is reporting that facilities in Puerto Rico are now producing saline products

5/5 We are seeing the situation improve and we expect that we will be able to resolve these shortages well before next year’s flu season begins.

Today at @DrugInfoAssn #AdPromo18 #FDA Office of Rx Drug Promotion talks about the importance of #FDA social science research on advertising like identifying barriers to consumer understanding of risk information & identifying potential solutions http

At #FDA, we’re working closely with @SecAzar on crafting policy to improve competition, access, and opportunity for patients to benefit from safe, effective, and lower cost biosimilar alternatives. https://t.co/VfyO1nOt1f

RT @SecAzar: Thank you @SGottliebFDA for showing me around @US_FDA yesterday. Keep up the great work! https://t.co/CvXKeucKwm

RT @annaedney: FDA Commissioner @SGottliebFDA goes after a “rigged payment scheme” between PBMs, insurers and pharma for keeping l… https://t.co/rsnW83K8rb

RT @Surgeon_General: This a.m. I was in TN learning about how Knox County formed a Naloxone Community Collaborative to inform citizens a… https://t.co/EPHu8Yfg1O

RT @SecAzar: The most powerful force in the #healthcare marketplace is a fully informed consumer. Greater transparency will help… https://t.co/2Uy3JF3KXN

RT @CDCDirector: More than 100 Americans die each day from #opioid overdoses – in every town across the nation. Here’s how we can re… https://t.co/xRHStw1Glh

RT @Reuters_Health: FDA head Gottlieb criticizes industry for 'Kabuki drug-pricing' https://t.co/jA4p6ewIwD

RT @CDCgov: Influenza activity has declined significantly, but will likely continue for several more weeks. Help stop the sprea… https://t.co/dsAEwjbd5W

RT @FDA_Track: Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA activities related to the ongoing post-market review o… https://t.co/sJXblrNjaA

My perspectives piece in @NEJM tonight with CBER Center Director Peter Marks on balanced innovation, access, and safety with cell-based regenerative medicine https://t.co/W6BBqSObRV

RT @HHSGov: Curious about #biosimilars? They are a safe and effective treatment options for patients. https://t.co/1DC8jak8hI… https://t.co/U2knIzNzSi

1/5 I want to provide brief update on shortage of IV saline products which was exacerbated by flu season, and impact of Hurricane Maria on medical product manufacturing sector in Puerto Rico.

RT @SecAzar: I spent some time at @US_FDA and @FDA_Drug_Info yesterday. I'm continually inspired by the great work being done by… https://t.co/qxbJ55TOiT

2/5 The products in shortage include large volume saline bags typically used to hydrate patients, such as those suffering from influenza, and small volume IV saline bags (generally in 50 and 100 ml sizes) that are often used to deliver other medicines.

New #FDA-authored special report in The New England Journal of Medicine says definitive studies regarding safety/efficacy of certain stem cell procedures are needed. Without studies, these therapies may be detrimental to patients, public health: https://t

Pleased to have co-authored a special report with @FDACBER Director Dr. Peter Marks made available today in The New England Journal of Medicine regarding the agency’s work balancing safety/innovation for cell-based regenerative medicine: https://t.co/9y0i

4/5 New manufacturers, Grifols and Fresenius Kabi, licensed last year, are now also online and producing saline products. Additionally, we’ve permitted imports of saline from 6 non-U.S. facilities and are encouraging them to get approval to help address t

3/5 We’ve actively work on improving large and small IV bag shortages for several months and continue to focus on this. In addition, existing manufacturers, most notably Baxter, is reporting that facilities in Puerto Rico are now producing saline products

5/5 We are seeing the situation improve and we expect that we will be able to resolve these shortages well before next year’s flu season begins.

Today at @DrugInfoAssn #AdPromo18 #FDA Office of Rx Drug Promotion talks about the importance of #FDA social science research on advertising like identifying barriers to consumer understanding of risk information & identifying potential solutions http